Literature DB >> 25737557

Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.

Kristen M Turner1, Youting Sun1, Ping Ji1, Kirsi J Granberg2, Brady Bernard3, Limei Hu1, David E Cogdell1, Xinhui Zhou1, Olli Yli-Harja4, Matti Nykter4, Ilya Shmulevich3, W K Alfred Yung5, Gregory N Fuller1, Wei Zhang6.   

Abstract

Akt is a robust oncogene that plays key roles in the development and progression of many cancers, including glioma. We evaluated the differential propensities of the Akt isoforms toward progression in the well-characterized RCAS/Ntv-a mouse model of PDGFB-driven low grade glioma. A constitutively active myristoylated form of Akt1 did not induce high-grade glioma (HGG). In stark contrast, Akt2 and Akt3 showed strong progression potential with 78% and 97% of tumors diagnosed as HGG, respectively. We further revealed that significant variations in polarity and hydropathy values among the Akt isoforms in both the pleckstrin homology domain (P domain) and regulatory domain (R domain) were critical in mediating glioma progression. Gene expression profiles from representative Akt-derived tumors indicated dominant and distinct roles for Akt3, consisting primarily of DNA repair pathways. TCGA data from human GBM closely reflected the DNA repair function, as Akt3 was significantly correlated with a 76-gene signature DNA repair panel. Consistently, compared with Akt1 and Akt2 overexpression models, Akt3-expressing human GBM cells had enhanced activation of DNA repair proteins, leading to increased DNA repair and subsequent resistance to radiation and temozolomide. Given the wide range of Akt3-amplified cancers, Akt3 may represent a key resistance factor.

Entities:  

Keywords:  Akt; DNA repair; RCAS/tv-a mouse model; glioma

Mesh:

Substances:

Year:  2015        PMID: 25737557      PMCID: PMC4371922          DOI: 10.1073/pnas.1414573112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Statistical issues in cDNA microarray data analysis.

Authors:  Gordon K Smyth; Yee Hwa Yang; Terry Speed
Journal:  Methods Mol Biol       Date:  2003

2.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

Authors:  Ioanna G Maroulakou; William Oemler; Stephen P Naber; Philip N Tsichlis
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 3.  Perturbations of the AKT signaling pathway in human cancer.

Authors:  Deborah A Altomare; Joseph R Testa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

4.  The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo.

Authors:  Peiyu Pu; Chunsheng Kang; Jie Li; Hao Jiang; Jinquan Cheng
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  Phase II study of perifosine in previously untreated patients with metastatic melanoma.

Authors:  D Scott Ernst; Elizabeth Eisenhauer; Nancy Wainman; Mary Davis; Reinhard Lohmann; Tara Baetz; Karl Belanger; Michael Smylie
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

6.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 7.  Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery.

Authors:  George Z Cheng; Sungman Park; Shaokun Shu; Lili He; William Kong; Weizhou Zhang; Zengqiang Yuan; Lu-Hai Wang; Jin Q Cheng
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

8.  The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

Authors:  Karen G Chee; Jeff Longmate; David I Quinn; Gurkamal Chatta; Jacek Pinski; Przemyslaw Twardowski; Chong-Xian Pan; Angelo Cambio; Christopher P Evans; David R Gandara; Primo N Lara
Journal:  Clin Genitourin Cancer       Date:  2007-12       Impact factor: 2.872

9.  Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Authors:  Rameen Beroukhim; Gad Getz; Leia Nghiemphu; Jordi Barretina; Teli Hsueh; David Linhart; Igor Vivanco; Jeffrey C Lee; Julie H Huang; Sethu Alexander; Jinyan Du; Tweeny Kau; Roman K Thomas; Kinjal Shah; Horacio Soto; Sven Perner; John Prensner; Ralph M Debiasi; Francesca Demichelis; Charlie Hatton; Mark A Rubin; Levi A Garraway; Stan F Nelson; Linda Liau; Paul S Mischel; Tim F Cloughesy; Matthew Meyerson; Todd A Golub; Eric S Lander; Ingo K Mellinghoff; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

10.  Insulin-like growth factor binding protein 2 promotes glioma development and progression.

Authors:  Sarah M Dunlap; Joseph Celestino; Hua Wang; Rongcai Jiang; Eric C Holland; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-02       Impact factor: 11.205

View more
  49 in total

1.  Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma.

Authors:  Chen Jin; Jie Zhao; Zhi-Ping Zhang; Ming Wu; Jian Li; Ge-Lei Xiao; Bo Liu; Yu-Xiang Liao; Jing-Ping Liu
Journal:  J Neurooncol       Date:  2020-05-29       Impact factor: 4.130

2.  OverAKT3: tumor progression and chemoresistance.

Authors:  Ping Ji; Kristen M Turner; Wei Zhang
Journal:  Cell Cycle       Date:  2015-04-30       Impact factor: 4.534

3.  Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.

Authors:  Bing Li; Chun Zhou; Liang Yi; Lunshan Xu; Minhui Xu
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

4.  Cyclical expression of GDNF is required for spermatogonial stem cell homeostasis.

Authors:  Manju Sharma; Robert E Braun
Journal:  Development       Date:  2018-03-01       Impact factor: 6.868

5.  Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.

Authors:  Michael L Miller; Jessica Tome-Garcia; Aneta Waluszko; Tatyana Sidorenko; Chitra Kumar; Fei Ye; Nadejda M Tsankova
Journal:  J Mol Diagn       Date:  2019-04-15       Impact factor: 5.568

Review 6.  Genome-Wide Association Studies in Glioma.

Authors:  Ben Kinnersley; Richard S Houlston; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01-30       Impact factor: 4.254

7.  Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.

Authors:  Casey Stottrup; Tiffany Tsang; Y Rebecca Chin
Journal:  Mol Cancer Ther       Date:  2016-06-13       Impact factor: 6.261

8.  The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.

Authors:  Anna Joy; Manisha Kapoor; Joseph Georges; Lacy Butler; Yongchang Chang; Chaokun Li; Acacia Crouch; Ivan Smirnov; Mitsitoshi Nakada; James Hepler; Max Marty; Burt G Feuerstein
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130

9.  LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis.

Authors:  Jianghong Hu; Guohua Ni; Ling Mao; Xianglong Xue; Jijie Zhang; Weixia Wu; Shaoru Zhang; Hong Zhao; Lifang Ding; Lihui Wang
Journal:  Onco Targets Ther       Date:  2019-09-24       Impact factor: 4.147

10.  Meta-Analyses of Splicing and Expression Quantitative Trait Loci Identified Susceptibility Genes of Glioma.

Authors:  C Pawan K Patro; Darryl Nousome; Rose K Lai
Journal:  Front Genet       Date:  2021-04-15       Impact factor: 4.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.